Guillain-Barré syndrome (GBS ... despite this therapy, some patients still make a slow or incomplete recovery. A recent study (Kuitwaard et al, 2009) aimed to examine whether pharmacokinetics ...

Swedish biotechnology firm Hansa Biopharma has announced that its investigational drug imlifidase improved motor function in patients with Guillain-Barré Syndrome (GBS) in a Phase II study.

As per the Guillain-Barré Syndrome (GBS) statistics shared by Maharashtra health department authorities with the public on ...

We present a case of Guillain-Barré syndrome in a child who received hepatitis A vaccine 5 days before onset of the clinical symptoms. In our patient, the association of Guillain-Barré syndrome ...

Given its investment in researching and treating the disease, Annexon recently launched Move GBS Forward, the first awareness campaign about the syndrome. Love explains that while physicians study GBS ...

SAN DIEGO -- A single dose of investigational tanruprubart resulted in rapid, sustained improvement in disability compared with placebo in patients with Guillain-Barré syndrome (GBS), a phase III ...

Peruvian authorities Saturday declared a 90-day nationwide sanitary emergency due to the “unusual increase” in cases of Guillain-Barré ... allocated to improving patient care, reinforcing ...

One person per 78,000 is diagnosed with Guillain-Barré syndrome annually, according to the Cleveland Clinic. Only about 3% of those patients are diagnosed with the pharyngeal-cervical-brachial ...